错配修复缺陷转移性结直肠癌患者一线免疫检查点抑制剂治疗中转移部位与临床结局的关系
在法国多中心回顾性队列(n=66)中验证美国队列数据并汇总分析(n=104),所有患者接受一线免疫检查点抑制剂单药治疗。肝转移(而非其他部位)与更差的客观缓解(P=0.03)和无进展生存显著相关(验证队列HRadj 2.82,95%CI 1.08-7.39,Padj=0.03;汇总分析HRadj 3.18,95%CI 1.52-6.67,Padj=0.002)。
要点
- 验证队列客观缓解率58%(38/66),其中完全缓解20%、部分缓解38%。
- 肝转移患者最佳肿瘤缓解减弱(P=0.03),其他转移部位无此关联。
- 肝转移是独立于协变量的无进展生存不良因素(汇总分析HRadj 3.18)。
核心结论
- 肝转移(而非其他部位)被验证为d-MMR mCRC患者接受免疫检查点抑制剂治疗后缓解和生存更差的独立因素。
- 作者认为这些数据强调需要为这类患者探索新的治疗策略。
研究设计与样本
- 法国多中心回顾性队列(n=66),旨在验证美国队列数据,并进行汇总分析(n=104)。
- 所有患者接受一线免疫检查点抑制剂单药治疗。
- 转移部位与肿瘤缓解(RECIST 1.1版)的关系采用多因素分层Cox回归分析,并校正协变量。
主要发现
- 验证队列客观缓解38/66(58%),最佳肿瘤缓解包括完全缓解13例(20%)、部分缓解25例(38%)、疾病稳定16例(25%)、疾病进展11例(17%)。
- 1年和5年无进展生存率分别为73%和67%;18例(27%)患者在免疫治疗期间进展。
- 肝转移患者最佳肿瘤缓解减弱(P=0.03)。
- 校正协变量后,肝转移(而非其他部位)与更差的无进展生存显著相关(HRadj 2.82;95%CI 1.08-7.39;Padj=0.03)。
- 汇总分析中,肝转移仍与更差的无进展生存独立显著相关(HRadj 3.18;95%CI 1.52-6.67;Padj=0.002),并与最佳肿瘤缓解减弱相关(P=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Only one-half of deficient mismatch repair (d-MMR) metastatic colorectal cancers (mCRC) demonstrate durable responses to immune checkpoint inhibitors (ICIs). Given preclinical data indicating that liver metastases sequester activated CD8+ T cells from systemic circulation, we examined clinical outcome by metastatic site. PATIENTS AND METHODS: In a retrospective cohort of patients with d-MMR mCRCs treated at multiple centers in France (n = 66), we sought to validate data from a U.S. cohort, and performed pooled analysis (n = 104). All patients received first-line ICI monotherapy. Metastatic site was analyzed in relationship to tumor response (RECIST version 1.1), and with progression-free survival (PFS) by multivariable stratified Cox regression after adjustment for covariates. RESULTS: Objective responses were achieved in 38/66 (58%) of patients in the validation cohort. Best tumor response included 13 (20%) complete responses (CR), 25 (38%) partial responses (PR), 16 (25%) stable disease, and 11 (17%) progressive disease (PD). One-year and 5-year PFS rates were 73% and 67%, respectively; 18 (27%) patients progressed during immunotherapy. Best tumor response was attenuated in patients with liver metastasis (P = 0.03). Presence of liver metastasis, but not other sites, was associated with significantly poorer PFS after adjustment for covariates (HRadj 2.82; 95%CI, 1.08-7.39; Padj=0.03). In a pooled analysis, liver metastasis remained significantly and independently associated with poorer PFS (HRadj 3.18; 95%CI, 1.52-6.67; Padj=0.002) and with attenuated tumor best response (P = 0.01). CONCLUSIONS: Metastasis to the liver, but not other sites, was validated as an independent factor associated with poorer response and survival after ICI treatment in d-MMR mCRCs. These data underscore the need for novel therapeutic strategies in these patients.
引用
- Saberzadeh-Ardestani B, Jones JC, McWilliams RR, et al. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting. Eur J Cancer. 2023. PMID: 37979306. doi:10.1016/j.ejca.2023.113433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。